IFNG and neoplasm: The limitations are due to several relapse mechanisms occurring during the anti-angiogenic therapies, including an upregulation of PD-L1 by cytotoxic T lymphocytes (CTL)-secreted IFN-γ (30), and abnormalities in the tumor endothelium (31).